Evidence map›Paper›PMID 40340136›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Modulation of antibody transport in the brain and spinal cord through the intranasal pathway.

Sebastian Spiegel, Sandrine Joly, Ivo Meli, Andrew Chan, Vincent Pernet

Abstract read

In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sebastian SpiegelDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Experimental Neurology Center (ZEN), Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Department of Biomedical Research, University Bern, 3010 Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3010 Bern, Switzerland.

Sandrine JolyDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Experimental Neurology Center (ZEN), Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Department of Biomedical Research, University Bern, 3010 Bern, Switzerland.

Ivo MeliDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Experimental Neurology Center (ZEN), Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Department of Biomedical Research, University Bern, 3010 Bern, Switzerland.

Andrew ChanDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Experimental Neurology Center (ZEN), Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Department of Biomedical Research, University Bern, 3010 Bern, Switzerland. Electronic address: Andrew.Chan@insel.ch.

Vincent PernetDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Experimental Neurology Center (ZEN), Bern University Hospital, University of Bern, 3010 Bern, Switzerland; Department of Biomedical Research, University Bern, 3010 Bern, Switzerland; Regenerative Medicine Unit, University Hospital Center of Quebec, Laval University, Quebec City, QC, Canada; Department of Molecular Medicine, Faculty of Medicine, Laval University, Quebec City, QC, Canada. Electronic address: Vincent.Pernet@insel.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intranasal pathway is a promising antibody delivery route for the treatment of neurological diseases, but the mechanisms mediating nose-to-brain/spinal cord transport are poorly understood. The aim of our study was to determine if the transport of antibodies can pharmacologically be modulated in the mouse CNS. The pharmacokinetics and distribution of recombinant antibodies were followed in brain and spinal cord homogenates and biofluids by ELISA and immunofluorescence. A non-CNS antigen-binding antibody (FG12) was used to monitor target-independent transport whereas 11C7 mAb, neutralizing the myelin-associated growth inhibitor Nogo-A, was applied to induce CNS target-dependent neuronal growth response. Fast axonal transport/neuronal activity were inhibited with Lidocaine pre-treatment on the olfactory mucosa. Antibody uptake was enhanced across the olfactory epithelium with the co-administration of the cell-penetrating peptide Penetratin. Growth signalling pathways were examined by Western blotting. FG12 was detected in the brain and spinal cord as early as 30 min after intranasal administration. After 1 h, the concentration of FG12 rapidly declined in all CNS areas and was back to baseline values at 24 h. Lidocaine prevented the early rise in FG12 concentration in the spinal cord. This effect was not observed in the brain. Penetratin allowed to maintain the elevation of FG12 and to activate 11C7-induced growth signalling in the spinal cord at 24 h. Our data suggest that the pharmacological modulation of transport mechanisms in the nose-to-CNS pathways may allow to control the therapeutic effects of antibodies in neurological diseases.

Indexed as

AntibodiesAntibodies, MonoclonalBrainSpinal CordAdministration, IntranasalAnimalsLidocaineMaleMiceMice, Inbred C57BLAntibodiesAntibodies, MonoclonalLidocaineBlood-brain barrierCell-penetrating peptideIntranasal pathwayNeuronal plasticityNogo-ARecombinant antibodies

Identifiers

PMID40340136

DOI10.1016/j.neurot.2025.e00606

PMCPMC12418472

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.